[Medical Newspaper] July 23, 2018
/In the June 11th and 12th articles titled “Where Does the ‘Moral Hazard’ of Stem Cell Companies End?” and the June 18th article titled “Serious ‘Moral Hazard’ in Stem Cell Companies,”
Miracell applied for a new medical technology assessment for “autologous bone marrow stem cell therapy for patients with cartilage defects.” However, the technology was determined to be research-level technology with unproven safety and efficacy.
Therefore, it cannot be commercially used in clinical settings. Furthermore, despite the fact that the reimbursement standards remained unchanged, Miracell spread false information claiming that “the age restriction for stem cell therapy for cartilage defects had been lifted,” and raised concerns about “moral hazard.”
But Miracell’s ‘Autologous bone marrow stem cell therapy for patients with cartilage defects’ was given a limited medical technology grade B in the new medical technology assessment. On May 29, 2018, it was confirmed that Miracell Co., Ltd. had been added to the list of technologies eligible for limited medical technology applications with confirmed safety. Therefore, it has been confirmed that Miracell Co., Ltd. did not spread false information, and we are correcting this.
This report is subject to the mediation of the Press Arbitration Commission.
Medical Newspaper medicalnews@bosa.co.kr